Evidence map›Paper›PMID 21507571›Full record

ArticleCancer letters2011

The taccalonolides, novel microtubule stabilizers, and γ-radiation have additive effects on cellular viability.

April L Risinger, Mohan Natarajan, Charles R Thomas, Susan L Mooberry

Abstract read
In one paragraph

Article in Cancer letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

April L RisingerDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States. Electronic address: risingera@uthscsa.edu.
Mohan NatarajanDepartment of Otolaryngology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.
Charles R ThomasDepartment of Radiation Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.
Susan L MooberryDepartment of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States. Electronic address: Mooberry@uthscsa.edu.

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1M
Taccalonolides: Mechanisms of Action and Cellular ResistanceR01CA121138 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI MOOBERRY, SUSAN L · 2006 to 2016
$2.7M
ENHANCED APOPTOSIS BY TARGETING PROTEIN REDOX STATUSR01CA112175 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI NATARAJAN, MOHAN · 2006 to 2009
$705k
NCI NIH HHS P30 CA054174NCI NIH HHS R01 CA112175NCI NIH HHS R01 CA121138
6 · The paper itself

Abstract

The taccalonolides are novel antimitotic microtubule stabilizers that have a unique mechanism of action independent of a direct interaction with tubulin. Cytotoxicity and clonogenic assays show that taccalonolide A and radiation act in an additive manner to cause cell death. The taxanes and epothilones have utility when combined with radiotherapy and these findings further suggest the additive effects of microtubule targeting agents with radiation on cellular proliferation are independent of direct tubulin binding and are instead a result of the downstream effects of these agents. These studies suggest that diverse antimitotic agents, including the taccalonolides, may have utility in chemoradiotherapy.

Indexed as

Gamma RaysBreast NeoplasmsCarcinoma, Squamous CellCell CycleCell ProliferationCombined Modality TherapyFemaleHumansMicrotubulesMouth NeoplasmsSteroidsTumor Cells, CulturedTumor Stem Cell AssaySteroidstaccalonolide Ataccalonolide E

Identifiers

PMID21507571
PMCPMC3104079

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.